首页> 外文OA文献 >Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction

【2h】

Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction

机译：一线诱导化疗后表现良好状态仍未进展的IIIb / IV期非小细胞肺癌（NSCLC）患者维持治疗的贝叶斯网络元比较：按表现状态，EGFR突变，组织学和对既往反应的结果感应

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Tan Pui San; Lopes Gilberto; Acharyya Sanchalika; Bilger Marcel; Haaland Benjamin;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction [J] . Tan Pui San, Lopes Gilberto, Acharyya Sanchalika, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2015,第16期

机译：一线诱导化疗后表现良好状态仍未进展的IIIb / IV期非小细胞肺癌（NSCLC）患者维持治疗的贝叶斯网络荟萃比较：按表现状态，EGFR突变，组织学和对既往反应的结果感应
2. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. [J] . Yang CH, Yu CJ, Shih JY, Journal of Clinical Oncology . 2008,第16期

机译：特定的EGFR突变可预测接受一线吉非替尼单药治疗的初治非化疗非小细胞肺癌IIIB / IV期患者的治疗结果。
3. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. [J] . Salazar F, Molina MA, Sanchez Ronco M, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2011,第1期

机译：IV期非小细胞肺癌患者与EGFR酪氨酸激酶抑制剂作为二线治疗相比，血清CHFR的一线治疗和甲基化状态影响化疗的结果。
4. The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy [O] . Yuan Wang, Guo-fang Hu, Zhe-hai Wang 2017

机译：IIIB或IV期非小细胞肺癌患者的免疫抑制状态与临床特征和对化疗的反应有关
5. P2-316: Phase II trial of pemetrexed and gemcitabine as first-line chemotherapy for elderly and/or poor performance status patients with stage iiib/iv non-small cell lung cancer (NSCLC) [O] . Schwartzberg Lee S., Blakely Johnetta, Keaton Mark, 2007

机译：P2-316：培美曲塞和吉西他滨作为一线化疗用于iiib / iv期非小细胞肺癌（NSCLC）的老年和/或表现不佳患者的一线化疗的II期试验

Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction

著录项

相似文献

相关主题

期刊订阅